Company Hua Medicine (Shanghai) Ltd.

Equities

2552

KYG4644K1022

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for Hua Medicine (Shanghai) Ltd.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2024-04-26 am EDT			5-day change	1st Jan Change
1.62 ^HKD	+1.89%		+8.00%	-17.77%

Mar. 28	Hua Medicine Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Hua Medicine Ltd. Appoints Yi Zhang as Executive Director with Effect from January 1, 2024	CI

Hua Medicine is a China-based company principally engaged in the drug development business. The Company is mainly engaged in the development of an oral drug, Dorzagliatin, or HMS5552, for the treatment of Type 2 diabetes. The Company mainly operates its business in the domestic and overseas markets.

Number of employees: 177

HKD in Million	2021	Weight	2022	Weight	Delta
Drugs for Diabetes 100.0 %	0	nan %	20	100.0 %	-

HKD in Million	2021	Weight	2022	Weight	Delta
China 100.0 %	0	nan %	20	100.0 %	-

Managers	Title	Age	Since
Li Chen FOU	Founder	61	09-11-09
Li Changhong CTO	Chief Tech/Sci/R&D Officer	55	-
Di Hong COO	Chief Operating Officer	45	21-04-30
Yun Long Du CTO	Chief Tech/Sci/R&D Officer	-	17-08-11
Fuxing Tang CTO	Chief Tech/Sci/R&D Officer	57	20-02-12
Yi Zhang CTO	Chief Tech/Sci/R&D Officer	-	18-03-31
Chien Cheng Lin BRD	Director/Board Member	53	18-09-12
Wenjie Xu SAM	Sales & Marketing	52	18-08-08
Wing Yan Yuen SEC	Corporate Secretary	53	19-12-30

Members of the board	Title	Age	Since
Robert Nelsen CHM	Chairman	60	10-04-22
William Keller BRD	Director/Board Member	75	-
Yiu Wa Tsui BRD	Director/Board Member	74	18-08-31
Li Chen FOU	Founder	61	09-11-09
Yi Zhang CTO	Chief Tech/Sci/R&D Officer	-	18-03-31
Chien Cheng Lin BRD	Director/Board Member	53	18-09-12
Yiu Leung Cheung BRD	Director/Board Member	64	22-12-31
Fang Xin Li BRD	Director/Board Member	32	23-10-11

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	1,055,588,761	911,594,906 ( 86.36 %)	76,866,704 ( 7.282 %)	86.36 %

Name	Equities	%	Valuation
Fang Hong Xing 3.337 %	35,220,690	3.337 %	7 M $
Chien Cheng Lin 0.8052 %	8,499,295	0.8052 %	2 M $
CRUX Asset Management Ltd. 0.3851 %	4,065,069	0.3851 %	763 501 $
Li Chen 0.3427 %	3,618,000	0.3427 %	679 533 $
Fullgoal Fund Management Co., Ltd. 0.0171 %	180,000	0.0171 %	33 808 $
The Core Trust Co., Ltd. 0.000000 %	0	0.000000 %	- $

Hua Medicine Ltd.

Lane 36, Xuelin Road Building 2

201203, Shanghai

http://www.huamedicine.com

address Hua Medicine (Shanghai) Ltd.(2552)

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.5 CNY

Average target price

3.072 CNY

Spread / Average Target

+104.89%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
HUA MEDICINE (SHANGHAI) LTD.	-17.77%	203M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs